Vaxart Inc (VXRT)
0.7575
-0.03
(-4.05%)
USD |
NASDAQ |
Oct 31, 16:00
0.7575
0.00 (0.00%)
After-Hours: 20:00
Vaxart Cash from Financing (Quarterly): 38.24M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 38.24M |
| March 31, 2024 | 18.20M |
| December 31, 2023 | -0.066M |
| September 30, 2023 | -0.008M |
| June 30, 2023 | 13.90M |
| March 31, 2023 | 1.42M |
| December 31, 2022 | 8.596M |
| September 30, 2022 | 4.988M |
| June 30, 2022 | 2.838M |
| March 31, 2022 | 1.04M |
| December 31, 2021 | 0.505M |
| September 30, 2021 | 20.64M |
| June 30, 2021 | 37.06M |
| March 31, 2021 | 67.59M |
| December 31, 2020 | 5.10M |
| September 30, 2020 | 98.61M |
| June 30, 2020 | 15.06M |
| March 31, 2020 | 19.54M |
| December 31, 2019 | -2.228M |
| September 30, 2019 | 7.755M |
| June 30, 2019 | 8.31M |
| March 31, 2019 | 2.123M |
| December 31, 2018 | -0.519M |
| September 30, 2018 | -0.468M |
| June 30, 2018 | -0.477M |
| Date | Value |
|---|---|
| March 31, 2018 | -0.265M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | |
| June 30, 2017 | -0.20M |
| March 31, 2017 | -0.10M |
| December 31, 2016 | -0.10M |
| September 30, 2016 | |
| June 30, 2016 | 18.00M |
| March 31, 2016 | -0.10M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | -0.10M |
| June 30, 2015 | -0.10M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 26.80M |
| December 31, 2013 | |
| September 30, 2013 | |
| September 30, 2012 | -24.48M |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.017M |
| September 30, 2011 | 0.121M |
| June 30, 2011 | 0.23M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.228M
Minimum
Dec 2019
98.61M
Maximum
Sep 2020
18.48M
Average
8.596M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 2.441M |
| Perspective Therapeutics Inc | 122.08M |
| Protalix BioTherapeutics Inc | 0.00 |
| Electromed Inc | -0.075M |
| Armata Pharmaceuticals Inc | 0.088M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -12.03M |
| Cash from Investing (Quarterly) | -9.664M |
| Free Cash Flow | -62.42M |
| Free Cash Flow Per Share (Quarterly) | -0.0671 |
| Free Cash Flow to Equity (Quarterly) | -12.40M |
| Free Cash Flow to Firm (Quarterly) | -12.20M |
| Free Cash Flow Yield | -50.91% |